Pharmazz, Inc.
Clinical trials sponsored by Pharmazz, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New stroke drug enters final testing phase – could improve recovery Results expected Sep 2026 (estimated)
- New drug could save lives from shock after severe bleeding Results expected Nov 2026 (estimated)
- Could a new drug save Babies' brains after oxygen loss? Results expected Nov 2026 (estimated)
- New stroke drug shows promise in major trial Results expected Sep 2027 (estimated)
-
Could a shock drug help ARDS patients breathe easier?
Disease control Not yet recruitingThis study tests an experimental drug called centhaquine in 80 adults with moderate to severe ARDS, a life-threatening lung condition. The drug is added to standard care to see if it improves oxygen levels and reduces deaths. Participants must be in the ICU and start treatment wi…
Phase 2 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug aims to save lives from shock due to blood loss
Disease control Not yet recruitingThis study tests a new medicine called centhaquine for people in hypovolemic shock, a life-threatening condition where the body doesn't have enough blood flow. About 430 adults will receive either centhaquine or a placebo along with standard care. The main goal is to see if the d…
Phase 3 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC